TY - JOUR
T1 - Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma
AU - Vanazzi, Anna
AU - Grana, Chiara
AU - Crosta, Cristiano
AU - Pruneri, Giancarlo
AU - Rizzo, Stefania
AU - Radice, Davide
AU - Pinto, Antonello
AU - Calabrese, Liliana
AU - Paganelli, Giovanni
AU - Martinelli, Giovanni
PY - 2014
Y1 - 2014
N2 - We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma-arisen at any extranodal site-received 90Y-ibritumomab tiuxetan at the activity of 0.4mCi/kg. Median age was 57years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3years, 12 of them after >5years. 90Y-ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients.
AB - We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma-arisen at any extranodal site-received 90Y-ibritumomab tiuxetan at the activity of 0.4mCi/kg. Median age was 57years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3years, 12 of them after >5years. 90Y-ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients.
KW - Lymphoma
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84895522384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895522384&partnerID=8YFLogxK
U2 - 10.1002/hon.2078
DO - 10.1002/hon.2078
M3 - Article
C2 - 23696416
AN - SCOPUS:84895522384
VL - 32
SP - 10
EP - 15
JO - Hematological Oncology
JF - Hematological Oncology
SN - 0278-0232
IS - 1
ER -